Levetiracetam Tablet, Film Coated
Product Images NDC 43547-883

This text provides formulas for estimating the Glomerular Filtration Rate (GFR) using age, weight, gender, and serum creatinine levels. The first formula calculates GFR for males and the second formula adjusts for females by multiplying with 0.85. Serum creatinine values are also included in the calculation. The results can help assess kidney function in patients.*

The text provides information about the Responder Rate (>50% Reduction From Baseline) in Study 1. It shows the percentages of responders for each group: Placebo (N=95), Levetiracetam 1000 mg/day (N=37), and Levetiracetam 3000 mg/day (N=101). The results indicate that at the specified doses, Levetiracetam (both 1000 mg/day and 3000 mg/day) had statistically significant efficacy compared to the placebo in achieving a >50% reduction from baseline.*

The provided text is a summary of a study comparing the responder rate of participants with a >50% reduction from baseline in Study 2 during Period A. The study involved three groups: a placebo group (N=111) and two groups treated with different doses of Levetiracetam (1000 mg/day N=106 and 2000 mg/day N=105). The data presented in the figure shows the responder rates for each group, with some percentages marked as statistically significant versus placebo.*

This text presents data on the Responder Rate (>50% Reduction From Baseline) in Study 3 for Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). It shows the respective percentages of patients exhibiting >50% reduction from baseline in response to treatment with each. The text also notes that the results were statistically significant compared to placebo.*

This text provides information from a study showing the Responder Rate, expressed as a percentage reduction from the baseline, in Study 4. The Responder Rate for the placebo group was 19.6%, while for the levetiracetam group it was significantly higher at 46%. The data displayed in a graphical form, with percentage values shown for both groups.*

This is a statistical data table showing the percentage of patients with different results, with a note indicating that some values are statistically significant compared to a placebo. The data includes percentages such as 45%, 35%, 30%, 20%, 19.6%, and 43.1%. The drug mentioned is "Levetiracetam".*

This text presents Figure 6 from a study evaluating the Responder Rate (50% Reduction from Baseline) in primary generalized tonic-clonic (PGTC) seizures per week. It compares the responder rates of patients receiving placebo and levetiracetam. The results show a statistically significant difference in efficacy between levetiracetam and placebo.*

This is information about Levetiracetam tablets, each containing 250 mg of the active ingredient. The tablets should be stored in a tightly closed, light-resistant container with a child-resistant closure at room temperature. The manufacturer is Prinston Laboratories, and they are distributed in the US by Solco Healthcare. Pharmacists are instructed to dispense a Medication Guide along with the tablets to each patient. Additional dosage information can be found in the enclosed package insert or online.*

This text provides information about levetiracetam tablets containing 500 mg of the active ingredient. It includes instructions to store the medication at room temperature and in a light-resistant container with a child-proof closure. The text also mentions the manufacturer and distributor of the medication, along with a reference to the package insert for dosage information.*

This is a medication information sheet for Levetiracetam tablets. Each tablet contains 750 mg of levetiracetam, USP. The tablets should be stored in a tight, light-resistant container with a child-resistant closure at a temperature between 20-25 °C (68-77 °F) with permitted excursions to 15-30 °C (59-86 °F). The package insert provides dosage information. The medication is distributed by Solco Healthcare US, LLC and manufactured by Prinston Laboratories in the USA. Pharmacists are instructed to dispense the Medication Guide separately to each patient. For more information, a medication guide can be found online at www.solcohealthcare.com/medguide/levetiracetam-tablets-pl.pdf.*

This text is a prescription label for levetiracetam tablets containing 1,000 mg each. The medication should be stored in a light-resistant container with a child-resistant closure at room temperature. It also provides information on how to access the medication guide online and includes details about the manufacturer and distributor of the medication.*